

A Review on Liposomal Drug Delivery System

Khomanesupriyasantosh, Rokade Anita Suresh, Veer Sujata U., Dr. Khedkar Amol. N.

Saikrupa Institute of Pharmacy, Ghargaon, Maharashtra

Abstract: Liposomes is lipoids bilayer, which have been first prepared by Bangham and others in 1961. They having extraordinarily drug entrapment efficiency. Due to their size, hydrophobic and lipophilic character they're most extensively used carriers for drug delivery. The main goal of this drug transport gadget is to target the drug immediately to the website online of movement so that you can lengthen and decorate the drug effect. Liposomes are biologically compatible and are able to entrap hydrophilic as well as lipophilic drug inside its compartment. They are available in different sizes varies from 0.05-5.0 μ in diameter. Numerous conventional techniques used for liposomal preparation and size reduction are mechanical dispersion strategies, solvent dispersion strategies and detergent elimination approach. Due to distinction in method of preparation and composition of lipids, liposomes may be characterised in step with length, price, lamellarity and so forth. This text provide a top level view of liposomes, benefits, disadvantages, mechanism of movement, classification, structural composition, training as well as evaluation parameters, programs and future elements.

Keywords: Liposomes, bilayer vesicles, drug entrapment, hydrophobic, hydrophilic etc

REFERENCES

- [1] Vyas SP, Khar RK (2002), “Targeted and Controlled Drug Delivery”, 1st Edition. CBS Publishers; New Delhi.
- [2] Patel Chirag. Available at <https://www.pharmatutor.org/articles/liposomes-novel-drug-delivery-carrier>. Retrieved on April 27, 2020.
- [3] Maripati S, Umashankar K, Reddy PJ; “A Review on Liposomes”; International Journal of Research in Pharmaceutical and Nano Sciences;2014; 3(3); 159-169.
- [4] Yadav D, Sandeep K, Pandey D, Dutta RK (2017); “Liposomes for Drug Delivery”; J Biotechnol Biomater 7: 276.
- [5] Sharma D, Ali AAE, Trivedi LR; “An Updated Review On: Liposomes as Drug Delivery System”; Pharmatutor; 2018; 6(2); 50-62.
- [6] Joshi AJ, et al. Liposomes: “Emerging Trends in Novel Drug Delivery with Present and Future Challenges”. IJPBA.2014; 6(2): 3-8.
- [7] Wu F, Bhansali SG, Tamhane M, Kumar R., Vathy LA, Ding H, Yong K, Bergey EJ, Prasad PN (2012); “Noninvasive Real-Time Fluorescence Imaging of Lymphatic Uptake of BSA-IR Dye 680 Conjugate Administered Subcutaneously in Mice”; Morris MEJ Pharm Sci.; 101(5); 1744-54.
- [8] Engelking Larry R (2015); “Textbook of Veterinary Physiological Chemistry”, 3rd Edition. Academic Press, USA; <Https://Doi.Org/10.1016/B978-0-12-391909-0.50059-1>.
- [9] RukhsanaYusaf et al.; “Structural Components of Liposomes and Characterization Tool”; Indo American Journal of Pharma Research.2014;4(08).
- [10] Shashi Kant, Satinder Kumar, Parashar Bharat (2012); “A Complete Review On: Liposomes”; International Research Journal of Pharmacy; 3(7); 10-16.
- [11] Gallagher ES, Mansfield E, Aspinwall CA (2014); “Stabilized Phospholipid Membranes in Chromatography: Toward Membrane Protein-Functionalized Stationary Phases”; Anal Bioanal Chem.; 406(9-10); 2223–2229.
- [12] Deepa SG. Available at <https://www.pharmatutor.org/articles/liposomes-overview-novel-trend-drug-delivery>. Retrieved on March 24, 2020.
- [13] AnwekarHimanshu, Patel Sitasharan, and Singhai A. K (2011); “Liposome- As Drug Carriers”; International Journal of Pharmacy and Life Science; 2(7); 945-951.



- [14] Van Hoogevest P and Wendel A (2011); “The Use of Natural and Synthetic Phospholipids as Pharmaceutical Excipients”; European Journal of Lipid Science and Technology; 116(9); 1088-1107.
- [15] Martin B, Sainlos M, Aissaoui A, Oudrhiri N, Hauchecorne M, Vigneron JP, Lehn JM, Lehn P (2005); “The Design of Cationic Lipids for Gene Delivery”; Current Pharmaceutical Design; 11(3); 375-394.
- [16] Joshi AJ, et al. Liposomes: “Emerging Trends in Novel Drug Delivery with Present and Future Challenges”. IJPBA.2014; 6(2): 3-8.
- [17] OlgoPoposka, Klopcevska Zoran, RafajlovakaVesna (2013); “An Overview: Methods for Preparation and Characterization of Liposomes as Drug Delivery System”; International Journal of Pharm. Phytopharmacological Research; 3(3); 182-189.
- [18] Vemuri S, Yu Ching D, Wangsatorntanakun V, Roosdorp N (1990); “Large-Scale Production of Liposomes by a Microfluidizer”; Drug Dev Ind Pharm; 16(15); 2243-2256.
- [19] Akbarzadeh et al. “Nanoscale Research Letters”; 2013, 8:102; Page 4-9 <http://Www.Nanoscalereslett.Com/Content/8/1/102>.
- [20] V Deepthi and ANKavithr (2014); “Liposomal Drug Delivery System-a Review”; RGUHS J Pharma Sci.; 4(2); 47-56.
- [21] Argan Nikhil, Harikumar SL, Nirmala (2012); “Topicsl Liposomal Gel: a Novel Drug Delivery System”; IJRPC; 2(2); 383-391.
- [22] Kirby CJ, Gregoriadis G. (1980); Life Sciences; 27; 2223.
- [23] Mayer LD, Hope MJ, Cullis RP, Janoff AS. (1985); Biochim. Biophys. Acta 817; 193.
- [24] Ohsawa T, Miura H, Harada K, (1985); Pharm. Bull. 33, 2916.
- [25] Ong SGM, Chitneni M, Lee KS, Ming LC, Yuen KH (2016); “Evaluation of Extrusion Technique for Nanosizing Liposomes”; Pharmaceutics; 8(4); 36.
- [26] Dua JS, Rana AC, Bhandari AK (2012); “Liposome: Method of preparation and applications”; International Journal of Pharmaceutical Studies; 3(2); 14-20.
- [27] Thakur Varun, Arora Sonia, Prashar Bharat, Patil Vishal (2012); “Niosomes and Liposomes- Vesicular Approach towards Transdermal Drug Delivery”; International Journal of Pharmaceutical and Chemical Sciences; 1(3); 981-993.
- [28] Szoka Francis, Papahadjopoulos D. (1978); “Procedure for Preparation of Liposomes with Large Internal Aqueous Space and High Capture by Reverse Phase Evaporation”; Proceedings of the National Academy of Sciences of America; 75(9); 4194-4198.
- [29] Gatt S, Bercovier JH and Barenholz Y. (1991); “Use of liposomes to combat oil spills and their potential application to bioreclamation, in: On Site Bioreclamation, Eds R.E. Hinchee and R.F. Olfenbuttel (Butterworth, Stoneham); 293–312.
- [30] Kuhlencord, A, Maniera, T, Eibl, H and Unger, C; “Antimicrob. Agents Chemother.” 36:1992, 1630–1634.
- [31] Bangham A.D., Horne R.W. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. *J. Mol. Biol.* 1964;8:660–668.
- [32] Mirzavi F., Barati M., Soleimani A., Vakili-Ghartavol R., Jaafari M.R., Soukhtanloo M. A review on liposome-based therapeutic approaches against malignant melanoma. *Int. J. Pharm.* 2021;599:120413.
- [33] Wang G., Li R., Parseh B., Du G. Prospects and challenges of anticancer agents’ delivery via chitosan-based drug carriers to combat breast cancer: A review. *Carbohydr. Polym.* 2021;268:118192.
- [34] Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. *Vaccine.* 2012;30:2256–2272.
- [35] Man F., Gawne P.J., de Rosales R.T.M. Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine. *Adv. Drug Delivery Rev.* 2019;143:134–160.
- [36] Dos Santos Rodrigues B., Banerjee A., Kanekiyo T., Singh J. Functionalized liposomal nanoparticles for efficient gene delivery system to neuronal cell transfection. *Int. J. Pharm.* 2019;566:717–730.



- [37] Taha E.I., El-Anazi M.H., El-Bagory I.M., Bayomi M.A. Design of liposomal colloidal systems for ocular delivery of ciprofloxacin. *Saudi Pharm. J.* 2014;22:231–239.
- [38] Han Y., Gao Z., Chen L., Kang L., Huang W., Jin M., Wang Q., Bae Y.H. Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins. *Acta Pharm. Sin. B.* 2019;9:902–922.
- [39] Mirtaleb M.S., Shahraky M.K., Ekrami E., Mirtaleb A. Advances in biological nano-phospholipid vesicles for transdermal delivery: A review on applications. *J. Drug Delivery Sci. Technol.* 2021;61:102331.
- [40] Mehta P.P., Ghoshal D., Pawar A.P., Kadam S.S., Dhapte-Pawar V.S. Recent advances in inhalable liposomes for treatment of pulmonary diseases: Concept to clinical stance. *J. Drug Delivery Sci. Technol.* 2020;56:101509.
- [41] Yusuf H., Ali A.A., Orr N., Tunney M.M., Mc Carthy H.O., Kett V.L. Novel freeze-dried DDA and TPGS liposomes are suitable for nasal delivery of vaccine. *Int. J. Pharm.* 2017;533:179–186. doi: 10.1016/j.ijpharm.2017.09.011.
- [42] Liu W., Hou Y., Jin Y., Wang Y., Xu X., Han J. Research progress on liposomes: Application in food, digestion behavior and absorption mechanism. *Trends Food Sci. Technol.* 2020;104:177–189.
- [43] Himeno T., Konno Y., Naito N. Liposomes for Cosmetics. In: Sakamoto K., Lochhead R.Y., Maibach H.I., Yamashita Y., editors. *Cosmetic Science and Technology*. Elsevier; Amsterdam, The Netherlands: 2017. pp. 539–549.
- [44] Niu M., Lu Y., Hovgaard L., Guan P., Tan Y., Lian R., Qi J., Wu W. Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: The effect of cholate type, particle size and administered dose. *Eur. J. Pharm. Biopharm.* 2012;81:265–272.
- [45] Wang N., Wang T., Li T., Deng Y. Modulation of the physicochemical state of interior agents to prepare controlled release liposomes. *Colloids Surf. B.* 2009;69:232–238.
- [46] Zeng H., Qi Y., Zhang Z., Liu C., Peng W., Zhang Y. Nanomaterials toward the treatment of Alzheimer's disease: Recent advances and future trends. *Chin. Chem. Lett.* 2021;32:1857–1868.
- [47] Li C., Zhang Y., Wan Y., Wang J., Lin J., Li Z., Huang P. STING-activating drug delivery systems: Design strategies and biomedical applications. *Chin. Chem. Lett.* 2021;32:1615–1625.
- [48] Forssen E.A. The design and development of DaunoXome® for solid tumor targeting in vivo. *Adv. Drug Delivery Rev.* 1997;24:133–150.
- [49] Kalyane D., Raval N., Maheshwari R., Tambe V., Kalia K., Tekade R.K. Employment of enhanced permeability and retention effect (EPR): Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer. *Mater. Sci. Eng. C Mater. Biol Appl.* 2019;98:1252–1276.
- [50] Zhang M., Gao S., Yang D., Fang Y., Lin X., Jin X., Liu Y., Liu X., Su K., Shi K. Influencing factors and strategies of enhancing nanoparticles into tumors in vivo. *Acta Pharm. Sin. B.* 2021;11:2265–2285.
- [51] Dana P., Bunthot S., Suktham K., Surassmo S., Yata T., Namdee K., Yingmema W., Yimsoo T., Ruktanonchai U.R., Sathornsumetee S., et al. Active targeting liposome-PLGA composite for cisplatin delivery against cervical cancer. *Colloids Surf. B Biointerfaces.* 2020; 196:111270.
- [52] Hashemi M., Shamshiri A., Saeedi M., Tayebi L., Yazdian-Robati R. Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs. *Arch. Biochem. Biophys.* 2020;691:108485.
- [53] Fernandes M.A., Eloy J.O., Luiz M.T., Junior S.L.R., Borges J.C., de la Fuente L.R., Luis C.O.S., Marchetti J.M., Santos-Martinez M.J., Chorilli M. Transferrin-functionalized liposomes for docetaxel delivery to prostate cancer cells. *Colloids Surf. A.* 2021;611:125806.
- [54] Danhier F., Breton A.L., Preat V. RGD-based strategies to target alphav beta3 integrin in cancer therapy and diagnosis. *Mol. Pharm.* 2012;9:2961–2973.
- [55] Kang T., Gao X., Hu Q., Jiang D., Feng X., Zhang X., Song Q., Yao L., Huang M., Jiang X., et al. iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas. *Biomaterials.* 2014;35:4319–4332.



- [56] Liang H., Zou F., Liu Q., Wang B., Fu L., Liang X., Liu J., Liu Q. Nanocrystal-loaded liposome for targeted delivery of poorly water-soluble antitumor drugs with high drug loading and stability towards efficient cancer therapy. *Int. J. Pharm.* 2021;599:120418.
- [57] Chen Q., Gao M., Li Z., Xiao Y., Bai X., Boakye-Yiadom K.O., Xu X., Zhang X.-Q. Biodegradable nanoparticles decorated with different carbohydrates for efficient macrophage-targeted gene therapy. *J. Control. Release.* 2020;323:179–190.
- [58] Pattni B.S., Chupin V.V., Torchilin V.P. New Developments in Liposomal Drug Delivery. *Chem. Rev.* 2015;115:10938–10966.
- [59] Kim T., Kim J., Kim S. Extended-release formulation of morphine for subcutaneous administration. *Cancer Chemother. Pharmacol.* 1993;33:187–190.
- [60] Fan Y., Marioli M., Zhang K. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery. *J. Pharm. Biomed. Anal.* 2021;192:113642. 34. Wang N., Chen M., Wang T. Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization. *J. Control. Release.* 2019;303:130–150.
- [61] Barenholz Y. DoxilThe first FDA-approved nano-drug: Lessons learned. *J. Control. Release.* 2012;160:117–134.
- [62] Dicko A., Kwak S., Frazier A.A., Mayer L.D., Liboiron B.D. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. *Int. J. Pharm.* 2010;391:248–259.

